UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of basic and clinical physiology and pharmacology, ISSN 0792-6855, 11/2019, Volume 30, Issue 6
Journal Article
Clinical infectious diseases, ISSN 1058-4838, 12/2014, Volume 59, Issue 12, pp. 1777 - 1778
Journal Article
Journal of hepatology, ISSN 0168-8278, 2013, Volume 59, Issue 3, pp. 434 - 441
Gastroenterology and Hepatology | Cirrhosis | Boceprevir | Chronic hepatitis C | Treatment | Telaprevir | Safety | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Prospective Studies | Humans | Middle Aged | Hepatitis C, Chronic - virology | Male | Hepatitis C, Chronic - complications | Oligopeptides - adverse effects | Serine Proteinase Inhibitors - adverse effects | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | France | Proline - administration & dosage | Liver Cirrhosis - drug therapy | Liver Cirrhosis - etiology | Serine Proteinase Inhibitors - administration & dosage | Proline - analogs & derivatives | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Interferon-alpha - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Proline - adverse effects | Aged | Interferon-alpha - adverse effects | Oligopeptides - administration & dosage | Viral Load - drug effects | Cohort Studies | Care and treatment | Hepatitis C virus | Liver cirrhosis | Analysis | Index Medicus | Life Sciences
Journal Article
Journal of hepatology, ISSN 0168-8278, 2013, Volume 60, Issue 1, pp. 78 - 86
Gastroenterology and Hepatology | Boceprevir | Protease inhibitors | Early virological response | HCV recurrence | Sustained virological response | Telaprevir | Drug-drug interaction | Liver transplantation | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Liver Transplantation | Humans | Middle Aged | Hepatitis C, Chronic - virology | Male | Hepatitis C, Chronic - drug therapy | Protease Inhibitors - adverse effects | Adult | Female | Aged | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Cohort Studies | Antiviral agents | Proteases | Liver | Transplantation | Hepatitis C virus | Hepatitis C | Anti-HIV agents | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2405 - 2416
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiviral agents | General aspects | Viral hepatitis | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Young Adult | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Interferon-alpha - therapeutic use | Logistic Models | Hepatitis C, Chronic - drug therapy | Sequence Analysis, DNA | Antiviral Agents - adverse effects | Aged | Interferon-alpha - adverse effects | Peginterferon alfa-2b | Patient outcomes | Genetic aspects | Hepatitis C | Drug therapy | Comparative analysis | Health aspects | Fees & charges | Antiretroviral drugs | Liver diseases | Clinical trials | Chronic infection | Employees | Infections | Proteinase inhibitors | Genomes | Ribonucleic acid--RNA | Patients | Ribavirin | Liver cancer | Genotype & phenotype | Hepatitis | Skin | Interferon | Genotypes | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Hepatology research, ISSN 1386-6346, 05/2017, Volume 47, Issue 6, pp. 514 - 521
Journal Article
The New England journal of medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2417 - 2428
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiviral agents | General aspects | Viral hepatitis | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Recurrence | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Young Adult | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Logistic Models | Hepatitis C, Chronic - drug therapy | Sequence Analysis, DNA | Retreatment | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Aged | Interferon-alpha - adverse effects | Peginterferon alfa-2a | Patient outcomes | Genetic aspects | Hepatitis C | Drug therapy | Comparative analysis | Health aspects | Liver diseases | Cytokines | Leukopenia | Anemia | Infections | Ribonucleic acid--RNA | Ribavirin | Manuscripts | Genotype & phenotype | Consent | Interferon | Drug dosages | Genotypes | Neutropenia | Pharmaceuticals | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article
World journal of hepatology, ISSN 1948-5182, 2016, Volume 8, Issue 22, pp. 949 - 956
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2014, Volume 147, Issue 1, pp. 132 - 142.e4
Gastroenterology and Hepatology | Triple Therapy | Chronic Hepatitis C | DAA | CUPIC | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Recombinant Proteins - therapeutic use | Multivariate Analysis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Liver Cirrhosis - epidemiology | Treatment Failure | Aged, 80 and over | Adult | Female | Hepatitis C, Chronic - epidemiology | Drug Therapy, Combination | Liver Cirrhosis - drug therapy | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Comorbidity | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Proline - therapeutic use | Liver Cirrhosis - virology | Antiviral Agents - adverse effects | Proline - adverse effects | Aged | Cohort Studies | Care and treatment | Protease inhibitors | Proteases | Genetic aspects | Hepatitis C virus | Hepatitis C | Health aspects | Liver cirrhosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal of hepatology, ISSN 0168-8278, 2012, Volume 56, Issue 1, pp. S88 - S100
Gastroenterology and Hepatology | Direct acting antiviral drugs | Boceprevir | Telaprevir | Drug combinations | Hepatitis C virus | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Recombinant Proteins - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Humans | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Hepacivirus - genetics | RNA Replicase - antagonists & inhibitors | Hepatitis C, Chronic - drug therapy | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Cyclophilins - antagonists & inhibitors | Proline - therapeutic use | Proline - adverse effects | Protease Inhibitors - adverse effects | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Index Medicus
Journal Article
Journal of hepatology, ISSN 0168-8278, 2011, Volume 56, Issue 1, pp. 78 - 84
Gastroenterology and Hepatology | Sustained virological response | Chronic hepatitis C | Telaprevir | Peginterferon | Ribavirin | Genotypes | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Antiviral agents | Viral hepatitis | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Prospective Studies | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - adverse effects | Oligopeptides - adverse effects | Young Adult | Ribavirin - administration & dosage | Adult | Female | RNA, Viral - metabolism | Drug Therapy, Combination | Drug Eruptions - etiology | Hematologic Diseases - chemically induced | Japan | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Aged | Interferon-alpha - adverse effects | Oligopeptides - administration & dosage | Cohort Studies | Genetic aspects | Interferon | Universities and colleges | Hepatitis C | Hepatitis C virus | Index Medicus
Journal Article